JP2008511300A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008511300A5 JP2008511300A5 JP2007528791A JP2007528791A JP2008511300A5 JP 2008511300 A5 JP2008511300 A5 JP 2008511300A5 JP 2007528791 A JP2007528791 A JP 2007528791A JP 2007528791 A JP2007528791 A JP 2007528791A JP 2008511300 A5 JP2008511300 A5 JP 2008511300A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide variant
- hmgb1
- nucleic acid
- disease
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims description 35
- 108700010013 HMGB1 Proteins 0.000 claims description 35
- 101150021904 HMGB1 gene Proteins 0.000 claims description 35
- 102100037907 High mobility group protein B1 Human genes 0.000 claims description 35
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 229920001184 polypeptide Polymers 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 102000002689 Toll-like receptor Human genes 0.000 claims 4
- 108020000411 Toll-like receptor Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000017854 proteolysis Effects 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 claims 1
- 208000012657 Atopic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108700012434 CCL3 Proteins 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 1
- 108090000317 Chymotrypsin Proteins 0.000 claims 1
- 208000027205 Congenital disease Diseases 0.000 claims 1
- 108020004703 Cruciform DNA Proteins 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 108010059378 Endopeptidases Proteins 0.000 claims 1
- 102000005593 Endopeptidases Human genes 0.000 claims 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 108060004872 MIF Proteins 0.000 claims 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 101710118538 Protease Proteins 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 102000012607 Thrombomodulin Human genes 0.000 claims 1
- 108010079274 Thrombomodulin Proteins 0.000 claims 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 229960002376 chymotrypsin Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 208000036260 idiopathic disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000000503 lectinlike effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 101100273751 Caenorhabditis elegans cdc-42 gene Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 101710091881 GTPase HRas Proteins 0.000 description 1
- 102000018802 High Mobility Group Proteins Human genes 0.000 description 1
- 108010052512 High Mobility Group Proteins Proteins 0.000 description 1
- 102100022128 High mobility group protein B2 Human genes 0.000 description 1
- 102100022130 High mobility group protein B3 Human genes 0.000 description 1
- 101001045791 Homo sapiens High mobility group protein B2 Proteins 0.000 description 1
- 101001045794 Homo sapiens High mobility group protein B3 Proteins 0.000 description 1
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 description 1
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04425665.9 | 2004-09-03 | ||
| EP04425665 | 2004-09-03 | ||
| PCT/EP2005/009528 WO2006024547A2 (en) | 2004-09-03 | 2005-09-05 | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008511300A JP2008511300A (ja) | 2008-04-17 |
| JP2008511300A5 true JP2008511300A5 (https=) | 2011-10-13 |
| JP5622351B2 JP5622351B2 (ja) | 2014-11-12 |
Family
ID=35768125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007528791A Expired - Fee Related JP5622351B2 (ja) | 2004-09-03 | 2005-09-05 | プロテアーゼ抵抗性ヒトおよび非ヒトＨＭＧＢ１Ｂｏｘ−Ａ変異体、ならびにそれらの治療／診断への使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7635679B2 (https=) |
| EP (1) | EP1797118A2 (https=) |
| JP (1) | JP5622351B2 (https=) |
| KR (1) | KR101249287B1 (https=) |
| AU (1) | AU2005279308B2 (https=) |
| BR (1) | BRPI0514835A (https=) |
| CA (1) | CA2579094C (https=) |
| MX (1) | MX2007002557A (https=) |
| NZ (1) | NZ553809A (https=) |
| WO (1) | WO2006024547A2 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| US7647184B2 (en) | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
| DE60332358D1 (de) | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| CA2882022A1 (en) | 2003-09-11 | 2005-03-24 | Walter Newman | Monoclonal antibodies against hmgb1 |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| WO2006124477A2 (en) * | 2005-05-13 | 2006-11-23 | The Feinstein Institute For Medical Research | Combination therapy with inhibitors of hmgb and caspase for the treatment of inflammatory diseases |
| WO2007011606A2 (en) * | 2005-07-18 | 2007-01-25 | Critical Therapeutics, Inc. | USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS |
| EP2423305A1 (en) | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IX polypeptides and use thereof for treatment |
| WO2007149567A2 (en) | 2006-06-21 | 2007-12-27 | Musc Foundation For Research Development | Targeting complement factor h for treatment of diseases |
| AU2007296843C1 (en) | 2006-09-15 | 2012-08-16 | Creabilis Therapeutics S.P.A. | Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1 |
| DE602007013919D1 (de) * | 2006-09-15 | 2011-05-26 | Creabilis Therapeutics Spa | Polymerkonjugate von box-a von hmgb1 und box-a-varianten von hmgb1 |
| ES2654542T3 (es) | 2008-04-30 | 2018-02-14 | Genomix Co., Ltd. | Procedimiento de recolección de células funcionales in vivo con alta eficiencia |
| US20120165244A1 (en) * | 2008-10-30 | 2012-06-28 | Hua-Lin Wu | Methods for binding lewis y antigen |
| JP5871798B2 (ja) | 2009-07-02 | 2016-03-01 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 肝再生を刺激する方法 |
| EP2492281B1 (en) * | 2009-10-19 | 2018-04-11 | HanAll Biopharma Co., Ltd. | Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same |
| US11191786B2 (en) | 2009-10-28 | 2021-12-07 | StemRIM Inc. | Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood |
| MX2012005151A (es) | 2009-11-05 | 2012-08-23 | Federico Ii University Of Naples | Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular. |
| WO2011143637A1 (en) | 2010-05-14 | 2011-11-17 | The Regents Of The University Of Colorado, A Body Corporate | Improved complement receptor 2 (cr2) targeting groups |
| US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
| US10272040B2 (en) | 2010-08-12 | 2019-04-30 | Nanyang Technological University | Liposomal formulation for ocular drug delivery |
| KR101279641B1 (ko) * | 2011-01-05 | 2013-06-27 | 인하대학교 산학협력단 | Ｈｉｈｐ－２를 유효성분으로 함유하는 신경보호용 조성물 |
| EP2703487B1 (en) * | 2011-04-26 | 2018-06-27 | Genomix Co., Ltd. | Peptide for inducing regeneration of tissue and use thereof |
| WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
| US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
| AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| DK2913059T3 (en) | 2012-10-25 | 2018-06-25 | Genomix Co Ltd | Hitherto UNKNOWN PROCEDURE FOR TREATMENT OF SPINE INJURY USING HMGB1 FRAGMENT |
| AU2013335684B2 (en) | 2012-10-25 | 2017-06-29 | Osaka University | Novel method for treating cardiac infarction using HMGB1 fragment |
| US9956195B2 (en) * | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
| GB201508337D0 (en) | 2015-05-15 | 2015-06-24 | Hmgbiotech S R L | Novel peptides |
| AU2016366515A1 (en) | 2015-12-11 | 2018-06-21 | Ruprecht-Karls-Universität Heidelberg | Combined preparations of PKM2 modulators and HMGB1 |
| US11969459B2 (en) | 2017-01-27 | 2024-04-30 | StemRIM Inc. | Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure |
| AU2018257071B2 (en) * | 2017-04-25 | 2021-11-11 | Shionogi & Co., Ltd. | Peptide for inducing regeneration of tissue, and use thereof |
| CA3084013A1 (en) | 2017-12-01 | 2019-06-06 | StemRIM Inc. | Ectodermal mesenchymal stem cells and method for producing same |
| WO2019107530A1 (ja) * | 2017-12-01 | 2019-06-06 | 株式会社ステムリム | 炎症性腸疾患の治療薬 |
| WO2019156137A1 (ja) | 2018-02-08 | 2019-08-15 | 株式会社ステムリム | 乾癬の治療薬 |
| US12304933B2 (en) | 2018-10-05 | 2025-05-20 | StemRIM Inc. | Disease treatment drug based on mesenchymal-stem-cell mobilization |
| WO2020085506A1 (ja) * | 2018-10-25 | 2020-04-30 | 国立大学法人大阪大学 | 軟骨疾患の治療薬 |
| US11684653B2 (en) * | 2019-03-06 | 2023-06-27 | The Cleveland Clinic Foundation | Compositions and method for reducing virulence of microorganisms |
| JP7455433B2 (ja) * | 2020-04-22 | 2024-03-26 | チュラーロンコーン ユニバーシティー | Ｄｎａを回復する及びｄｎａ損傷を防止する組成物及び方法 |
| CN113151329B (zh) * | 2021-03-30 | 2023-09-08 | 云南师范大学 | 中性蛋白酶突变体及其构造方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US7754217B2 (en) * | 2001-03-16 | 2010-07-13 | Bio3 Research Srl | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| US7304034B2 (en) * | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| EP1392844A4 (en) * | 2001-05-15 | 2006-09-06 | Long Island Jewish Res Inst | USE OF HMG FRAGMENTS AS ANTI-INFLAMMATORY AGENTS |
| US20060204537A1 (en) * | 2002-06-21 | 2006-09-14 | Genzyme Corporation | Silicone blends and composites for drug delivery |
| EP1539950A1 (en) * | 2002-09-09 | 2005-06-15 | Nautilus Biotech | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| PL376169A1 (en) * | 2002-11-15 | 2005-12-27 | Novartis Ag | Drug delivery system |
| CA2506328A1 (en) * | 2002-11-20 | 2004-06-03 | Critical Therapeutics, Inc. | Use of hmgb fragments as anti-inflammatory agents |
| JP2004222953A (ja) * | 2003-01-22 | 2004-08-12 | Kanegafuchi Chem Ind Co Ltd | 生体留置用ステント |
| CH694905A5 (it) * | 2003-03-25 | 2005-09-15 | Marco Ostini | Peptidi derivati dalla proteina HMGB1 per l'immunoterapia attiva nell'infiammazione sistematica letale. |
| WO2005025604A2 (en) * | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
-
2005
- 2005-09-05 NZ NZ553809A patent/NZ553809A/en not_active IP Right Cessation
- 2005-09-05 KR KR1020077007416A patent/KR101249287B1/ko not_active Expired - Fee Related
- 2005-09-05 MX MX2007002557A patent/MX2007002557A/es unknown
- 2005-09-05 CA CA2579094A patent/CA2579094C/en not_active Expired - Fee Related
- 2005-09-05 AU AU2005279308A patent/AU2005279308B2/en not_active Ceased
- 2005-09-05 BR BRPI0514835-9A patent/BRPI0514835A/pt not_active Application Discontinuation
- 2005-09-05 JP JP2007528791A patent/JP5622351B2/ja not_active Expired - Fee Related
- 2005-09-05 EP EP05790365A patent/EP1797118A2/en not_active Ceased
- 2005-09-05 WO PCT/EP2005/009528 patent/WO2006024547A2/en not_active Ceased
-
2007
- 2007-03-05 US US11/713,789 patent/US7635679B2/en not_active Expired - Fee Related
-
2009
- 2009-11-09 US US12/614,805 patent/US8058232B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008511300A5 (https=) | ||
| TWI817968B (zh) | 作為C5aR抑制劑之經二芳基取代之5,5-稠合環化合物 | |
| Vandenbark et al. | Microglia and astrocyte involvement in neurodegeneration and brain cancer | |
| JP5622351B2 (ja) | プロテアーゼ抵抗性ヒトおよび非ヒトＨＭＧＢ１Ｂｏｘ−Ａ変異体、ならびにそれらの治療／診断への使用 | |
| Hawkes et al. | Psoriasis pathogenesis and the development of novel targeted immune therapies | |
| EP1768677B1 (en) | Nucleic acids for the treatment of hmgb1-related pathologies | |
| Chen et al. | Extracellular HMGB1 as a proinflammatory cytokine | |
| Garlanda et al. | IL-1 family cytokines in inflammation and immunity | |
| CN111788185B (zh) | 作为C5a抑制剂的二芳基取代的6,5稠合环化合物 | |
| JP2010503630A5 (https=) | ||
| JP2017200930A (ja) | ＨＭＢＧ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体 | |
| AU779221B2 (en) | Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies | |
| RU2458070C2 (ru) | Конъюгаты с полимером а-бокса hmgb1 и вариантов а-бокса hmgb1 | |
| Wheeler et al. | The changing face of cytokines in the brain: perspectives from EAE | |
| CN103626865B (zh) | 具有趋化活性的分泌蛋白及其编码序列和医药用途 | |
| Shan et al. | Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A | |
| RU2785549C2 (ru) | ДИАРИЛ-ЗАМЕЩЕННЫЕ 5,5 СОПРЯЖЕННЫЕ ЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ C5aR | |
| RU2796983C2 (ru) | ДИАРИЛ-ЗАМЕЩЕННЫЕ 6,5-СОПРЯЖЕННЫЕ ЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ C5aR | |
| JPWO2014148638A1 (ja) | Ｉｌ−１７に対するアプタマー及びその使用 | |
| Pugin | The role of the macrophage |